Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M851Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-76.9EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)19.2Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book2.810-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.9PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M14,000,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PJP

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

PJP is held by these investors:

PJP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48541.56view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94259.03view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1735676.47view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.364372.06view
Bebek, IvanDirector 2017-01-16Buy8,990$3.381699.41view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4114734.15view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91117.91view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27870.02view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.380.73view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1540446.67view

Quarterly/Annual Reports about PJP:

    News about PJP:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback Feb 09 2017
    Q4 Earnings Faring Well for Pharma ETFs Feb 06 2017
    Changes in Bristol-Myers Squibb’s 4Q16 Profitability Feb 01 2017
    Why Eli Lilly Expects to See Revenue Growth in 4Q16 Jan 25 2017
    What Lies Ahead for Pharma ETFs? Jan 19 2017
    Trending: Pound Gains as Theresa May Lays out Brexit Plan Jan 19 2017
    Mylan’s Profit Margins: What Made Them Change? Jan 13 2017
    Understanding Mylan’s Revenues Jan 12 2017
    Harvoni: Gilead Sciences’ Blockbuster HCV Drug Jan 03 2017
    How Could Pfizer Drive Growth for Ibrance? Dec 12 2016
    Pisani: Trump rally is evolving Dec 07 2016
    Two Nano-Cap Pharma Stocks To Watch Right Now Dec 02 2016
    Understanding Merck’s Most Recent Product Developments Dec 01 2016
    How Baxter Continues to Contribute to Patient Care Dec 01 2016
    Steady Rise: Allergan’s International Segment in 3Q16 Nov 30 2016
    How Did Gilead Sciences’s HCV Business Perform across Geographies? Nov 29 2016
    How Was Bristol-Myers Squibb’s Profitability in 3Q16? Nov 29 2016
    Gilead Sciences Holds a Broader HIV Portfolio Nov 28 2016
    Bristol-Myers Squibb Continues Revenue Growth in 3Q16 Nov 25 2016
    Key Investor Insights into Eli Lilly’s Recent Developments Nov 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)